Neuropore Therapies, Inc.
10835 Road to the Cure, Suite 210
13 articles with Neuropore Therapies, Inc.
Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment of Cancers and Other Life-Threatening Diseases
Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology. This portfolio of small molecule autophagy modulators, targeting PI3K and VPS34, was discovered by Neuropore Therapies and characterized using its comprehensive platform of autophagy and lysosomal biogenesis cellular a
Neuropore Therapies Receives $500,000 Grant from The ALS Association to Explore ALS Treatments that Inhibit Neuronal Damage from Disease-Related Inflammation
Feb. 17, 2020 13:01 UTC SAN DIEGO--( BUSINESS WIRE )-- Neuropore Therapies, Inc., a biopharmaceutical company discovering and developing novel therapeutics for the treatment of neurodegenerative disorders, announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made
Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Neuropore Therapies, Inc. announced that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34.
Neuropore is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease
Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis
Neuropore Therapies, Inc. announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS.
Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence
Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.
UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration
Neuropore Therapies, Inc. announced that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America.
Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Neuropore Therapies, Inc. announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34.
Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research
Neuropore Therapies announced today that it received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative disorders.